Fig. 8: Clinical significance of the NDRG1/EGFR pathway in CRC patients with CTX treatment.
From: NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer
A Representative IHC images of two CRC cases showed the negative correlation between NDRG1 and EGFR, Cav1. Image examination contrasted the reaction of CTX treatment in these two cases (white arrow: liver metastases). B OS of the colorectal cancer patients with NDRG1, EGFR, and Cav1 expression. (Log-rank test). C PFS of the colorectal cancer patients with NDRG1, EGFR, and Cav1 expression. (Log-rank test). D OS and PFS curves of the colorectal cancer patients which stratified by NDRG1 and Cav1. The quantitative data were presented as mean ± SD. (NS no significant, *p < 0.05, **p < 0.01, ***p < 0.001).
